Adult T-Cell Leukemia-Lymphoma

Abeloff's Clinical Oncology: Fifth Edition

Volumn , Issue , 2013, Pages 2076-2092.e5

  Tsukasaki, Kunihiro ^a   Watanabe, Toshiki ^b   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84910047334     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2865-7.00108-9     Document Type: Chapter

References (239)

1. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419.
3. Miyoshi I, Kubonishi I, Sumida M, et al. A novel T-cell line derived from adult T-cell leukemia. Jpn J Cancer Res 1980, 71:155-156.
4. Miyoshi I, Kubonishi I, Yoshimoto S, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981, 294:770-771.
5. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: Antigen in adult T-cell leukemia cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981, 78:6476-6480.
6. Yoshida M, Miyoshi I, Hinuma Y Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79:2031-2035.
7. Watanabe T, Seiki M, Yoshida M ATLV (Japanese isolated) and HTLV (US isolated) are the same strain of retrovirus. Virology 1984, 133:238-241.
8. Tajima K The 4th nationwide study of adult T-cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features. Int J Cancer 1990, 45:237-243. T- and B-cell Malignancy Study Group.
9. Akagi T, Ono H, Shimotohno K Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood 1995, 86:4243-4249.
10. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984, 81:2534-2537.
11. Seiki M, Eddy R, Shows TB, Yoshida M Nonspecific integration of the HTLV-1 provirus genome into adult T-cell leukemia. Nature 1984, 309:640-642.
12. Seiki M, Hikikoshi A, Taniguchi T, Yoshida M Expression of the pX gene of HTLV-1: General splicing mechanism in the HTLV-1 family. Science 1985, 228:1532-1534.
13. Franchini G, Nicot C, Johnson JM Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003, 89:69-132.
14. Grassmann R, Aboud M, Jeang KT Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005, 24:5976-5985.
15. Nicot C, Harrod RL, Ciminale V, et al. Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. Oncogene 2005, 24:6026-6034.
16. Edwards D, Fenizia C, Gold H, et al. Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence. Viruses 2011, 3:861-885.
17. Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115:449-459.
18. Sagara Y, Ishida C, Inoue Y, et al. 71-Kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human T-cell lymphotropic virus type 1. J Virol 1998, 72:535-541.
19. Pinon JD, Klasse PJ, Jassal SR, et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003, 77:9922-9930.
20. Ghez D, Lepelletier Y, Lambert S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol 2006, 80:6844-6854.
21. Ghez D, Lepelletier Y, Jones KS, et al. Current concepts regarding the HTLV-1 receptor complex. Retrovirology 2010, 7:99.
22. Pais-Correia AM, Sachse M, Guadagnini S, et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16:83-89.
23. Marriott SJ, Semmes OJ Impact of HTLV-1 Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005, 24:5986-5995.
24. Pozzatti R, Vogel J, Jay G The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic trans-formation of cells. Mol Cell Biol 1990, 10:413-417.
25. Kadison P, Poteat HT, Klein KM, et al. Role of protein kinase A in tax transactivation of the human T-cell leukemia virus type I long terminal repeat. J Virol 1990, 64:2141-2148.
26. Harhaj EW, Sun SC IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem 1999, 274:22911-22914.
27. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science 1995, 269:79-81.
28. Franchini G, Wong-Staal F, Gallo RC Human T-cell leukemia virus (HTLV-1) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. Proc Natl Acad Sci U S A 1984, 81:6207-6211.
29. Kozuru M, Uike N, Takeichi N, et al. The possible mode of escape of adult T-cell leukaemia cells from antibody-dependent cellular cytotoxicity. Br J Haematol 1989, 72:502-506.
30. Tamiya S, Matsuoka M, Etoh K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996, 88:3065-3073.
31. Kitamura T, Takano M, Hoshino H, et al. Methylation pattern of human T-cell leukemia virus in vivo and in vitro: pX and LTR regions are hypomethylated in vivo. Int J Cancer 1985, 35:629-635.
32. Koiwa T, Usami-Hamano A, Ishida T, et al. 5'-LTR-selective CpG methylation of latent HTLV-1 provirus in vitro and in vivo. J Virol 2002, 76:9389-9397.
33. Loeb LA A mutator phenotype in cancer. Cancer Res 2001, 61. 3230-3229.
34. Gaudray G, Gachon F, Basbous J, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002, 76:12813-12822.
35. Satou Y, Yasunaga J, Yoshida M, et al. HTLV-1 basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006, 103:720-725.
36. Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 2001, 97:3612-3620.
37. Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: Correlation with clinical course. Blood 2001, 97:3875-3881.
38. Nagai H, Kinoshita T, Imamura J, et al. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 1991, 82:1421-1427.
39. Cesarman E, Chadburn A, Inghirami G, et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992, 80:3205-3216.
40. Hatta Y, Hirama T, Miller CW, et al. Homozygous deletions of the p15 (MTS-2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995, 85:2699-2704.
41. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 1997, 15:1778-1785.
42. Uchida T, Kinoshita T, Watanabe T, et al. The CDKN2 gene alterations in various types of adult T-cell leukaemia. Br J Haematol 1996, 94:665-670.
43. Tamiya S, Matsuoka M, Etoh K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996, 88:3065-3073.
44. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL: Frequent clonal change at crisis from indolent disease. Blood 1997, 89:948-956.
45. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
46. Osame M, Usuku K, Izumo S, et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet 1986, 1:1031-1032.
47. Tajima K, Inoue M, Takezaki T, et al. Ethnoepidemiology of ATL in Japan with special reference to the Mongoloid dispersal. Adult T-Cell Leukaemia 1994, 91-112. Oxford University Press, Oxford, UK. K. Takatsuki (Ed.).
48. Blattner WA, Gallo RC Epidemiology of HTLV-1 and HTLV-2 infection. Adult T-Cell Leukaemia 1994, 45-90. Oxford University Press, Oxford, UK. K. Takatsuki (Ed.).
49. Takezaki T, Hirose K, Hamajima N, et al. Estimation of adult T-cell leukemia incidence in Kyushu district from vital statistics Japan between 1983 and 1992: Comparison with a nationwide survey. Jpn J Clin Oncol 1997, 27:140-145.
50. Levine PH, Cleghorn F, Manns A, et al. Adult T-cell leukemia/lymphoma: A working point-score classification for epidemiological studies. Int J Cancer 1994, 59:491-493.
51. Tajima K HTLV-1/II related disease with special reference to its distribution among Mongoloids. Gann Monograph on Cancer Research, No. 44, Ethnoepidemiology of Cancer 1996, 207-217. Japanese Scientific Society Press, Tokyo. K. Tajima, S. Sonoda (Eds.).
52. Satake M, Yamaguchi K, Tadokoro K Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012, 84:327-335.
53. Hashimoto S, Funamoto T, Yamanaka R, et al. Study of the HTLV-I carrier status (distribution of carrier rate by districts): Report on the study of the prevention of mother-to-infant transmission of ATL 1991, Ministry of Health, Labour and Welfare, Tokyo, Japan.
54. Yamaguchi K, Nishimura Y, Kusumoto Y, et al. Declining trends of HTLV-1 prevalence among blood donors in Kumamoto, Japan. J AIDS 1992, 5:533-535.
55. Iwanaga M, Chiyoda S, Kusaba E, Kamihira S Trends in the seroprevalence of HTLV-1 in Japanese blood donors in Nagasaki Prefecture, 2000-2006. Int J Hematol 2009, 90:186-190.
56. Hino S, Yamaguchi K, Katamine S, et al. Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 1985, 76:474-480.
57. Okochi K, Sato H, Hinuma Y A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: Seroconversion in recipients. Vox Sang 1984, 46:245-253.
58. Brown LS, Chu A, Allain JP, et al. Seroepidemiology and clinical aspects of human T-cell lymphotropic virus type I/II infection in a cohort of intravenous drug users in New York City. N Y State J Med 1991, 91:93-97.
59. Hino S, Katamine S, Kawase K, et al. Intervention of maternal transmission of HTLV-1 in Nagasaki, Japan. Leukemia 1994, 8(Suppl 1):S68-S70.
60. Katamine S, Moriuchi R, Yamamoto T, et al. HTLV-I proviral DNA in umbilical cord blood of babies born to carrier mothers. Lancet 1994, 343:1326-1327.
61. Wilks R, Hanchard B, Morgan O, et al. Patterns of HTLV-I infection among family members of patients with adult T-cell leukemia/lymphoma and HTLV-I associated myelopathy/tropical spastic paraparesis. Int J Cancer 1996, 65:272-273.
62. Kondo T, Kondo H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-1 carriers. Int J Cancer 1989, 43:1061-1064.
63. Okamoto T, Ohno Y, Tsugane S, et al. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 1989, 80:191-195.
64. Yamada Y, Atogami S, Hasegawa H, et al. Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan. Rinsho Ketsueki 2011, 52:1765-1771.
65. Clark JW, Blattner WA, Gallo RC Human T-cell leukemia virus. Principles of Internal Medicine 1986, 29. McGraw-Hill, New York. J. Mendelsohn, R.G. Petersdorf, R.D. Adams (Eds.).
66. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990, 28:50-56.
67. Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989, 74:388-394.
68. Kanno M, Nakamura S, Matsuda T Adult T-cell leukemia with HTLV-I-associated myelopathy after complete remission of acute myelogenous leukemia. N Engl J Med 1998, 338:333.
69. Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001, 91:869-875.
70. Tamaki H, Matsuoka M Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006, 354:1758-1759.
71. Yoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T-cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant 2012, 12:1479-1485.
72. Kondo T, Kono H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989, 43:1061-1064.
73. Kawano F, Tsuda H, Yamaguchi K, et al. Unusual clinical courses of adult T-cell leukemia in siblings. Cancer 1984, 54:131-134.
74. Tokudome S, Shimamoto Y, Sumida I Smoking and adult T-cell leukemia/lymphoma. Eur J Cancer Prev 1993, 2:84-85.
75. Tsukasaki K, Yamada Y, Ikeda S, et al. Infective dermatitis among patients with ATL in Japan. Int J Cancer 1994, 57:293.
76. Hisada M, Okayama A, Shioiri S, et al. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998, 92:3557-3561.
77. Usuku K, Sonoda S, Osame M, et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann Neurol 1988, S143-S150.
78. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood 2010, 116:1211-1219.
79. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol 1991, 79:428-437. Shimoyama M and members of the Lymphoma Study Group (1984-1987).
80. Utsunomiya A, Hanada S, Terada A, et al. Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 1988, 61:824-828.
81. Yamada Y, Kamihira S, Murata K, et al. Frequent hepatic involvement in adult T-cell leukemia: Comparison with non-Hodgkin's lymphoma. Leuk Lymphoma 1997, 26:327-335.
82. Yoshioka R, Yamaguchi K, Yoshinaga T, et al. Pulmonary complications in patients with adult T-cell leukemia. Cancer 1985, 55:2491-2494.
83. Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1990, 65:327-332.
84. Amano M, Kurokawa M, Ogata K, et al. New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types. J Dermatol 2008, 35:270-275.
85. Bittencourt AL, da Graças Vieira M, et al. Adult T-cell leukemia/lymphoma in Bahia, Brazil: Analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol 2007, 128:875-882.
86. Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011, 117:3961-3967.
87. Motokura T, Fukumoto S, Matsumoto T, et al. Parathyroid hormone-related protein in adult T-cell leukemia/lymphoma. Ann Intern Med 1989, 111:484-488.
88. Watanabe T, Yamaguchi K, Takatsuki K, et al. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene. J Exp Med 1990, 172:759-765.
89. Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-β in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991, 77:2451-2455.
90. Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: Overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002, 99:634-640.
91. Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994, 73:2753-2758.
92. Tsukasaki K, Imaizumi Y, Tawara M, et al. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol 1999, 105:369-375.
93. Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Am J Surg Pathol 1984, 8:263-275.
94. Ohshima K, Jaffe ES, Kikuchi M Adult T-cell leukemia/lymphoma. WHO Classification of Tumour of Haemaopoietic and Lymphoid Tissues 2008, 281-284. IARC Press, Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
95. Ohshima K, Suzumiya J, Kato A, et al. Clonal HTLV-1-infected CD4+ T-lymphocytes and non-clonal non-HTLV-1-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 1997, 72:592-598.
96. Ohshima K Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci 2007, 98:772-778.
97. Nagatani T, Matsuzaki T, Iemoto G, et al. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Cancer 1990, 66:2380-2386.
98. Hall WW, Liu CR, Schneewind O, et al. Deleted HTLV-1 provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991, 253:317-320.
99. Kikuchi A, Nishikawa T, Ikeda Y, et al. Absence of human T-lymphotropic virus type I in Japanese patients with cutaneous T-cell lymphoma. Blood 1997, 89:1529-1532.
100. Bazarbachi A, Soriano V, Pawson R, et al. Mycosis fungoides and Sézary syndrome are not associated with HTLV-1 infection: An international study. Br J Haematol 1997, 98:927-933.
101. Saito S, Ando Y, Furuki K, et al. Detection of HTLV-1 genome in seronegative infants born to HTLV-1 seropositive mothers by polymerase chain reaction. Jpn J Cancer Res 1989, 80:808-812.
102. Kinoshita T, Imamura J, Nagai H, et al. Absence of HTLV-1 infection among seronegative subjects in an endemic area of Japan. Int J Cancer 1993, 54:16-19.
103. Dhawan S, Streicher HZ, Wahl LM, et al. Model for studying virus attachment: II. Binding of biotinylated human T cell leukemia virus type I to human blood mononuclear cells: Potential targets for human T cell leukemia virus type I infection. J Immunol 1991, 147:102-108.
104. Yamada Y Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood 1983, 61:192-199.
105. Tsuda H, Takatsuki K Specific decrease in T3 antigen density in adult T-cell leukemia cells: I. Flow microfluorometric analysis. Br J Cancer 1984, 50:843-845.
106. Shirono K, Hattori T, Hata H, et al. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood 1989, 73:1664-1671.
107. Kamihira S, Iwanaga M, Doi Y, et al. Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: Continuity from carrier status to smoldering ATL. Int J Hematol 2012, 95:399-408.
108. Tsuji T, Sugahara K, Tsuruda K, et al. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol 2004, 80:254-260.
109. Yamada Y, Kamihira S, Amagasaki T, et al. Adult T cell leukemia with atypical surface phenotypes: Clinical correlation. J Clin Oncol 1985, 3:782-788.
110. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003, 9:3625-3634.
111. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004, 126:81-84.
112. Kohno T, Yamada Y, Akamatsu N, et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005, 96:527-533.
113. Waldmann TA The IL-2/IL-15 receptor systems: Targets for immunotherapy. J Clin Immunol 2002, 22:51-56.
114. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115:4337-4343.
115. Vose J, Armitage J, Weisenburger D International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
116. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study. Leuk Res 1991, 15:81-90. Lymphoma Study Group.
117. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of p-glycoprotein in adult T-cell leukemia cells. Blood 1990, 76:2065-2071.
118. Shimoyama M Treatment of patients with adult T-cell leukemia-lymphoma: An overview. Advances in Adult T-cell Leukemia and HTLV-1 Research. Gann Monograph on Cancer Research, No. 39 1992, 43-56. Japanese Scientific Society Press, Tokyo. K. Takatsuki, Y. Hinuma, M. Yoshida (Eds.).
119. Shimoyama M Chemotherapy of ATL. Adult T-Cell Leukaemia 1994, 221-237. Oxford University Press, Oxford, UK. K. Takatsuki (Ed.).
120. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 2012, 30:1635-1640.
121. Fukushima T, Nomura S, Tsukasaki K, et al. Characterization of long term survivors and a predictive model for aggressive adult t-cell leukemia-lymphoma (ATL): An ancillary study by the Japan Clinical Oncology Group, JCOG0902A. Presented before the 53rd ASH annual meeting, 2011.
122. Combination chemotherapy with vincristine, cyclophosphamide (Endoxan), prednisolone and Adriamycin (VEPA) in advanced adult non-Hodgkin's lymphoid malignancies: Relation between T-cell or non-T-cell phenotype and response. Jpn J Clin Oncol 1979, 9(Suppl):397-406. Lymphoma Study Group.
123. Final results of cooperative study of VEPA [vincristine, cyclophosphamide (Endoxan), prednisolone and Adriamycin] therapy in advanced adult non-Hodgkin's lymphoma: Relation between T- or B-cell phenotype and response. Jpn J Clin Oncol 1982, 12:227-238. Lymphoma Study Group.
124. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988, 6:128-141.
125. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988, 6:1088-1097.
126. Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation "LSG4 protocol" in aggressive T- and B-lymphoma: A new predictive model for T- and B-lymphoma [abstract]. Proc Am Soc Clin Oncol 1994, 13:378.
127. Tsukasaki K, Tobinai K, Hotta T, et al. Lymphoma study group of JCOG. Jpn J Clin Oncol 2012, 42:85-95.
128. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003, 77:164-170.
129. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma (ATL): Japan Clinical Oncology Group (JCOG) Study 9303. Br J Haematol 2001, 113:375-382.
130. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study. (JCOG9801). J Clin Oncol 2007, 25:5458-5564.
131. Shimoyama M, Oyama A, Tajima K, et al. Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma. Leuk Lymphoma 1993, 10:335-342.
132. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:15-20.
133. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:829-834.
134. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
135. Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012, 119:2141-2148.
136. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012, 120:1734-1741.
137. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005, 105:4143-4145.
138. Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: Impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008, 14:702-708.
139. Choi I, Tanosaki R, Uike N, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 2011, 46:116-118.
140. Ichimaru M, Kamihira S, Moriuchi Y, et al. [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia.]. Gan To Kagaku Ryoho 1988, 15:2975-2981.
141. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332:1744-1748.
142. Hermine O, Blouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995, 332:1749-1751.
143. Tobinai K, Kobayashi Y, Shimoyama M, Gill PS, Harrington W, Levine AM Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma [correspondence]. N Engl J Med 1995, 333:1285-1286.
144. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001, 40:287-294.
145. Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000, 14:716-721.
146. Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108:1021-1109.
147. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183.
148. Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 2011, 29:4696-4701.
149. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009, 27:453-459.
150. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
151. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
152. Cheson BD, Pfistner B, Juweid ME, et al. The International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
153. Ohno R, Masaoka T, Shirakawa S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group. Cancer 1993, 71:2217-2221.
154. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990, 8:1907-1912.
155. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride. Br J Cancer 1994, 70:771-774.
156. Tobinai K, Hotta T, Saito H, et al. Combination phase I/II study of irinotecan hydrochloride and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1996, 26:455-460.
157. Ohtsu T, Sasaki Y, Igarashi T, et al. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. Jpn J Clin Oncol 1998, 28:502-506.
158. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
159. Marneros AG, Grossman ME, Silvers DN, et al. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. Blood 2009, 113:6338-6341.
160. Arima N, Mizoguchi H, Shirakawa S, et al. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma.]. Gan To Kagaku Ryoho 1999, 26:619-629.
161. Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 2003, 77:512-517.
162. Ogura M, Tsukasaki K, Nagai H, et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci 2012, 103:1290-1295.
163. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
164. Hasegawa H, Yamada Y, Tsukasaki K, et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011, 25:575-587.
165. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998, 103:721-728.
166. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93:278-283.
167. Kchour G, Tarhini M, Kooshyar M-M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
168. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 1993, 82:1701-1712.
169. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995, 86:4063-4075.
170. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000, 18:1622-1636.
171. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
172. Foss FM, Sjak-Shie NN, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. J Clin Oncol 2010, 28:15s.
173. Di Venuti G, Nawgiri R, Foss F Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma 2003, 4:176-178.
174. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002, 99:1505-1511.
175. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
176. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012, 30:837-842.
177. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
178. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy. Br J Haematol 2009, 145:173-179.
179. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
180. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003, 63:6453-6457.
181. Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α-refractory adult T-cell leukemia. Blood 2005, 106:3380-3382.
182. Ravandi F, Faderl S Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 2006, 30:103-105.
183. O'Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res 2009, 15:2514-2522.
184. Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008, 19:2079-2083.
185. Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004, 18:1357-1363.
186. Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541-4548.
187. Ogata M, Satou T, Kawano R, et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia. J Med Virol 2011, 83:702-709.
188. Greenberg SJ, Jaffe ES, Ehrlich GD, et al. Kaposi's sarcoma in human T-cell leukemia virus type I-associated adult T-cell leukemia. Blood 1990, 76:971-976.
189. Tobinai K, Ohtsu T, Hayashi M, et al. Epstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia-lymphoma. Leuk Res 1991, 15:837-846.
190. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
191. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419.
192. Miyoshi I, Kubonishi I, Sumida M, et al. A novel T-cell line derived from adult T-cell leukemia. Jpn J Cancer Res 1980, 71:155-156.
193. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: Antigen in adult T-cell leukemia cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981, 78:6476-6480.
194. Yoshida M, Miyoshi I, Hinuma Y Isolation and characterization of retrovirus from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79:2031-2035.
195. Tajima K The 4th nationwide study of adult T-cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features. Int J Cancer 1990, 45:237-243. T- and B-cell Malignancy Study Group.
196. Franchini G, Nicot C, Johnson JM Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003, 89:69-132.
197. Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115:449-459.
198. Pais-Correia AM, Sachse M, Guadagnini S, et al. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 2010, 16:83-89.
199. Franchini G, Wong-Staal F, Gallo RC Human T-cell leukemia virus (HTLV-1) transcripts in fresh and cultured cells of patients with adult T-cell leukemia. Proc Natl Acad Sci U S A 1984, 81:6207-6211.
200. Satou Y, Yasunaga J, Yoshida M, et al. HTLV-1 basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006, 103:720-725.
201. Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 2001, 97:3612-3620.
202. Cesarman E, Chadburn A, Inghirami G, et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992, 80:3205-3216.
203. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
204. Blattner WA, Gallo RC Epidemiology of HTLV-1 and HTLV-2 infection. Adult T-Cell Leukaemia 1994, 45-90. Oxford University Press, Oxford, UK. K. Takatsuki (Ed.).
205. Satake M, Yamaguchi K, Tadokoro K Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012, 84:327-335.
206. Hino S, Katamine S, Kawase K, et al. Intervention of maternal transmission of HTLV-1 in Nagasaki, Japan. Leukemia 1994, 8(Suppl 1):S68-S70.
207. Kondo T, Kondo H, Miyamoto N, et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-1 carriers. Int J Cancer 1989, 43:1061-1064.
208. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood 2010, 116:1211-1219.
209. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol 1991, 79:428-437. Shimoyama M and members of the Lymphoma Study Group (1984-1987).
210. Watanabe T, Yamaguchi K, Takatsuki K, et al. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene. J Exp Med 1990, 172:759-765.
211. Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: Overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002, 99:634-640.
212. Tsukasaki K, Imaizumi Y, Tawara M, et al. Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol 1999, 105:369-375.
213. Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Am J Surg Pathol 1984, 8:263-275.
214. Ohshima K, Jaffe ES, Kikuchi M Adult T-cell leukemia/lymphoma. WHO Classification of Tumour of Haemaopoietic and Lymphoid Tissues 2008, 281-284. IARC Press, Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
215. Kinoshita T, Imamura J, Nagai H, et al. Absence of HTLV-1 infection among seronegative subjects in an endemic area of Japan. Int J Cancer 1993, 54:16-19.
216. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003, 9:3625-3634.
217. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115:4337-4343.
218. Vose J, Armitage J, Weisenburger D International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
219. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study. Leuk Res 1991, 15:81-90. Lymphoma Study Group.
220. Shimoyama M Chemotherapy of ATL. Adult T-Cell Leukaemia 1994, 221-237. Oxford University Press, Oxford, UK. K. Takatsuki (Ed.).
221. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988, 6:1088-1097.
222. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003, 77:164-170.
223. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma (ATL): Japan Clinical Oncology Group (JCOG) Study 9303. Br J Haematol 2001, 113:375-382.
224. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study. (JCOG9801). J Clin Oncol 2007, 25:5458-5564.
225. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
226. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005, 105:4143-4145.
227. Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: Impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 2008, 14:702-708.
228. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332:1744-1748.
229. Hermine O, Blouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995, 332:1749-1751.
230. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183.
231. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009, 27:453-459.
232. Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 2003, 77:512-517.
233. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998, 103:721-728.
234. Kchour G, Tarhini M, Kooshyar M-M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
235. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 1993, 82:1701-1712.
236. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2Ra-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995, 86:4063-4075.
237. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
238. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012, 30:837-842.
239. Ogata M, Satou T, Kawano R, et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia. J Med Virol 2011, 83:702-709.